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The p53 protein acts a tumor suppressor by inducing cell cycle arrest and apoptosis in response to DNA
damage or oncogene activation. Recently, it has been proposed that phosphorylation of serine 15 in human p53
by ATM (mutated in ataxia telangiectasia) kinase induces p53 activity by interfering with the Mdm2-p53
complex formation and inhibiting Mdm2-mediated destabilization of p53. Serine 18 in murine p53 has been
implicated in mediating an ATM- and ataxia telangiectasia-related kinase-dependent growth arrest. To explore
further the physiological significance of phosphorylation of p53 on Ser18, we generated mice bearing a
serine-to-alanine mutation in p53. Analysis of apoptosis in thymocytes and splenocytes following DNA damage
revealed that phosphorylation of serine 18 was required for robust p53-mediated apoptosis. Surprisingly,
p53Ser18 phosphorylation did not alter the proliferation rate of embryonic fibroblasts or the p53-mediated G1
arrest induced by DNA damage. In addition, endogenous basal levels and DNA damage-induced levels of p53
were not affected by p53Ser18 phosphorylation. p53Ala18 mice developed normally and were not susceptible to
spontaneous tumorigenesis, and the reduced apoptotic function of p53Ala18 did not rescue the embryo-lethal
phenotype of Mdm2-null mice. These results indicate that phosphorylation of the ATM target site on p53
specifically regulates p53 apoptotic function and further reveal that phosphorylation of p53 serine 18 is not
required for p53-mediated tumor suppression.
The p53 tumor suppressor is a transcription factor that func-
tions to regulate cell proliferation and apoptosis. The impor-
tance of p53 in suppressing cancer is highlighted by the very
high incidence of spontaneous tumor formation in p53-defi-
cient mice and in mice bearing genetic alterations in other
members of the p53 pathway (14, 27, 30, 42). The critical role
of p53 in tumor suppression is further underscored by the high
frequency of p53 mutations in human cancer, and malignancies
that retain a wild-type p53 gene often have acquired other
mutations that affect one or more of the pathways known to
govern p53 function (53). Therefore, it is likely that inactiva-
tion of p53 is a common mechanistic step in the development
of most human cancers.
Cellular p53 activity is greatly increased following treatment
of cells with DNA-damaging agents such as ionizing radiation
and adriamycin (62). Induction of p53 activity can also occur in
response to inappropriate growth-stimulatory signals, such as
expression of an activated oncogene or exposure of the cells to
other forms of stress (37, 38, 50, 69). Increased p53 activity
resulting from DNA damage blocks the proliferation of cells in
the G1 phase of the cell cycle by inducing the expression of
genes such as the cyclin-dependent kinase inhibitor p21 (6, 13,
16, 20). In addition, increased p53 activity in the cell can
initiate apoptosis by inducting the expression of proapoptotic
BCL-2 family members involved in mitochondrion-associated
cell death and by transactivating the expression of death re-
ceptor-associated genes (7, 41, 52, 66). Both p53-mediated
inhibition of cell cycling and induction of apoptosis appear to
be highly dependent upon the cell context. Induction of p53
has also been proposed to regulate passage of cells through the
G2 phase of the cell cycle, chromosomal stability, and mitosis,
although the precise molecular mechanisms used by p53 to
perform these regulatory functions are less clear.
Given the multiple roles of p53 in controlling cell cycling and
cell death, proper regulation of p53 activity is obviously crucial
to permit cells to undergo normal growth and to respond
appropriately to stress. Regulation of cellular p53 activity has
been reported to occur at the level of p53 transcription and
translation (19, 49, 63). However, it is clear that Mdm2-medi-
ated alteration of p53 protein stability is a major pathway used
by many cells to govern p53 function. The Mdm2 oncoprotein
binds to the amino-terminal portion of the p53 protein (11,
48), induces p53 monoubiquitination and nuclear export (35,
39), and targets p53 for proteosomal degradation (23, 34). The
importance of Mdm2 as a negative regulator of p53 activity in
cell growth and development has been demonstrated in mice
by rescue of the embryo-lethal phenotype of Mdm2-deficient
mice by deletion of p53 (28, 45).
Numerous in vitro studies have determined that p53 is sub-
ject to posttranslational modification. Phosphorylation occurs
in response to DNA damage on human p53 serine residues 15
and 20 (mouse Ser18 and Ser23, respectively) and has been
found in several in vitro studies to upregulate p53 activity (15,
18, 36, 43, 60) and interfere with Mdm2-mediated degradation
of p53 (55).
The ATM (mutated in ataxia telangiectasia) kinase has been
demonstrated to phosphorylate human p53 serine 15 (3, 8, 33,
51). Furthermore, both human p53Ser15 phosphorylation (8,
46, 56) and total p53 protein levels (31, 32, 46) are reduced in
ATM-null cells following ionizing radiation treatment. These
observations suggest that ATM-mediated phosphorylation of
this residue increases the stability of p53. Expression of inac-
tive forms of the ataxia telangiectasia-related kinase ATR also
interferes with p53Ser15 phosphorylation (47, 58, 65). In ad-
dition, mouse embryonic fibroblasts (MEFs) deficient in both
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ATM and ATR fail to undergo G1 arrest in response to DNA
damage and display greatly reduced phosphorylation of
p53Ser18, the mouse homologue of human p53Ser15 (5).
These data suggest that ATM and ATR functions may depend,
in part, upon the ability of these related kinases to phosphor-
ylate p53 at this serine residue.
Recently mouse p53Ser18 was mutated in embryonic stem
(ES) cells, and the p53 apoptotic response and cell cycle arrest
following DNA damage of these cells were delayed (10). How-
ever, p53-mediated pathways of cell cycle inhibition and apo-
ptosis are not fully functional in ES cells (1). Thus, the rela-
tionship between p53Ser18 phosphorylation and p53 stability
and function remains unclear.
In order to directly address the role of p53Ser15 phosphor-
ylation in regulating p53 levels and p53 function in a geneti-
cally defined in vivo system, we used gene targeting in mouse
ES cells to generate mice bearing p53 alleles that contain a
p53Ser18 to Ala18 substitution. Our results indicate that the
p53-dependent apoptosis induced by ionizing radiation is sig-
nificantly reduced in the thymocytes and splenocytes of
p53Ala18/Ala18 mice. Therefore, phosphorylation of p53Ser18
regulates p53-dependent apoptosis. However, phosphorylation
of this residue does not alter the stability of the p53 protein.
Wild-type mice and p53Ala18 mice display similar basal p53
levels and similar induced levels of p53 following DNA dam-
age. Surprisingly, phosphorylation of p53Ser18 does not affect
the rate of cell proliferation of embryonic fibroblasts. In addi-
tion, loss of Ser18 does not alter the p53-dependent G1 arrest
of cell growth following DNA damage. Thus, the G1 arrest
induced by ATM and ATR following DNA damage is not
mediated by p53Ser18 phosphorylation. Furthermore, the re-
duced apoptotic activity of p53Ala18 does not rescue the em-
bryonic lethality of Mdm2-null mice and does not alter p53-
mediated tumor suppression. These results indicate that
phosphorylation of the ATM/ATR target serine 18 regulates
p53 apoptotic functions and not p53-mediated cell growth ar-
rest and that phosphorylation of this site is not required for p53
suppression of spontaneous tumorigenesis.
MATERIALS AND METHODS
Generation of targeted ES cells. The targeting vector was generated with a
portion of the p53 gene (129SVBrd-strain) spanning a BamHI fragment 9.9 kb
from intron 1 and intron 6 of the p53 gene. Serine 18 in exon 2 was mutated by
oligonucleotide site-directed mutagenesis (QuickChange kit; Stratagene) of a
subfragment of the targeting vector. The oligonucleotides used were HKS1Ala18
(5-GGATATCAGCCTCGAACTCCCTCTGGCCCAGGAGACATTTTCAG
G-3) and HKS2BAla (5-CCTGAAAATGTCTCCTGGGCCAGAGGGAGTT
CGAGGCTGATATCC-3). The subfragment was DNA sequenced to confirm
the mutation and subcloned back into the targeting vector. A neor cassette gene
flanked by loxP sites was introduced in an AvrII site, resulting in loss of the AvrII
site. An MC1-thymidine kinase gene was added to the 3 end of the targeting
vector.
Homologous recombination and generation of p53Ala18 mice. PC3 ES cells
(26) were electroporated with the targeting vector and drug selected with G418
and 1-(2-deoxy-2-fluoro--D-arabinofuranosyl-5-iodouracil (FIAU). A total of
600 ES clones were screened, and two correctly targeted clones were identified
by Southern analysis of EcoRI-digested genomic DNA with 5 and 3 probes
external to the targeting vector. The presence of the alanine mutation in the ES
clones was confirmed by PCR with oligonucleotide primers to intron1 forward
(1F; 5-GACAAGTTATGCATCATAC-3) and intron 3 reverse (3R; 5-CAAA
GCCCAAGTCCCTTTC-3) and subsequent digestion of the PCR fragments
with XhoI. The wild-type PCR product was digested to yield two fragments, 365
bp and 70 bp. Cells were microinjected into embryonic day 3.5 blastocysts
(C57BL/6 strain), and the embryos were surgically implanted into pseudopreg-
nant foster mice by standard procedures. Excision of the neor cassette in F1
offspring of male chimeric mice was confirmed by digestion with AvrII and
Southern analysis with a p53 exon 7 probe.
Research involving mice complied with all relevant federal and institutional
policies, as well as guidelines established by the Institutional Animal Care and
Use Committee at the University of Massachusetts Medical School.
Cell culture, proliferation, and immortalization assays. Murine embryonic
fibroblasts (MEFs) were generated from day 13.5 embryos from the various
genotypes and maintained in Dulbecco’s modified Eagle’s medium supplement
with 10% fetal bovine serum, penicillin, and streptomycin. Cells were maintained
at subconfluency, and low-passage MEFs (passages 2 to 4) were used for all
subsequent assays. Growth curves were performed with triplicate plating of
wild-type, p53/, p53Ala18/ and p53Ala18/Ala18 homozygous MEFs. Cells
were plated (5  105 cells/10-cm dish) and counted every 24 h with a Beckman
Coulter counter. Proliferation assays were performed with two independent lines
of each genotype. 3T3 assays were performed with multiple plates of each
genotype to examine rates of spontaneous immortalization as described previ-
ously (22).
DNA damage and cell cycle analysis. Replicative DNA synthesis was quanti-
fied by bivariate flow cytometry. In brief, cells were irradiated with 2, 5, or 8 Gy.
Cells were irradiated with a cesium 137 source (Gammacell 40). Cells were
pulsed with bromodeoxyuridine (60 M) from15 to 18 h postirradiation and
harvested by trypsinization and fixation in 70% ethanol. Fixed cells were washed
and incubated in 4 N HCl for 30 min at room temperature. The HCl was
neutralized by addition of 0.1 M borax. Cells were incubated with a fluorescein
isothiocyanate-conjugated antibromodeoxyuridine monoclonal antibody (Becton
Dickinson), washed, and resuspended in phosphate-buffered saline containing 50
g of RNase per ml and 20 g of propidium iodide per ml. Fluorescence from
propidium iodide complexes and fluorescein isothiocyanate-conjugated bro-
modeoxyuridine was measured by flow cytometry. Similar numbers of cells were
analyzed for each sample, and cell cycle distribution was determined with FlowJo
software.
Protein analysis and antibodies. Following treatment, cells were lysed in EBC
buffer (120 mM NaCl, 50 mM Tris-HCl, pH 8.0, 1.0% NP-40, 0.1% sodium
dodecyl sulfate, 1 mM EDTA) with a cocktail of protease and phosphatase
inhibitors; 100 g of cell extract were run on a sodium dodecyl sulfate-polyac-
rylamide gel electrophoresis gel. The p53 antibody (Ab-7 kit [Oncogene Re-
search Products], diluted 1:1,000), the phospho-p53 (Ser 15) (Cell Signaling
9284S, diluted 1:1,000), the Mdm2 antibody (Santa Cruz sc-812, diluted 1:500),
the p21 (Santa Cruz sc-397, diluted 1:500), the -tubulin antibody (Sigma, di-
luted 1:10,000), and the Puma antibody (Abcham Limited, diluted 1:1,000) were
obtained from the indicated suppliers. Immune complexes were detected by
enhanced chemiluminescence (ECL kit, Amersham).
Thymocyte and splenocyte studies. Thymocytes and splenic cells were re-
moved from 4- to 6-week-old mice. Thymuses were removed and ground up with
a syringe tip. Cells were washed with phosphate-buffered saline–1% serum so-
lution, and resuspended at 106 cells/ml in phosphate-buffered saline–1% serum.
For T-cell population profiling, whole animals were irradiated with 8 Gy. Thy-
mocytes were recovered from untreated and irradiated animals and stained with
CD4-phycoerythrin and CD8-fluorescein isothiocyanate antibodies (Pharmin-
gen). Thymocytes were then washed and fixed in 1% paraformaldehyde and
subjected to fluorescence-activated cell sorting analysis. For sub-G1 DNA anal-
ysis, whole animals were irradiated with 8 Gy. Thymocytes were removed 8 h
postirradiation from irradiated and control unirradiated animals. Thymocytes
were fixed in 70% ethanol. Sub-G1 DNA content was determined by fluores-
cence-activated cell sorting analysis.
Viability analysis was performed on in vitro-cultured thymocytes and thymo-
cytes derived from animals irradiated in vivo. For viability analysis, thymocytes
were stained with the annexin V-fluorescein isothiocyanate apoptosis kit (Onco-
gene Research Products). Viability was determined as the population negative
for annexin V/7-amino actinomycin D (7AAD) relative to unirradiated control
animals. Spleens were dissected and recovered as described (57). Splenocytes
were plated (2  105) in RPMI supplemented with 10% serum. Cells were
irradiated with 8 Gy. Viable cells were counted by trypan blue exclusion 7 days
post-ionizing radiation treatment.
RESULTS
Generation of p53Ala18 mice. To analyze the effect of p53
serine 18 phosphorylation on p53 functions, a gene targeting
experiment was performed in PC3 ES cells (129Sv-Brd strain).
A gene replacement vector containing strain 129 mouse p53
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genomic DNA was generated that encoded a serine to alanine
substitution at amino acid position 18 (Fig. 1A, D) in exon 2 of
the coding sequences. This substitution also deleted an XhoI
restriction endonuclease site in exon 2 DNA sequences without
altering the other amino acids encoded in exon 2. This vector
also contained a neomycin drug resistance marker flanked by
loxP sites inserted in intron 4 of the p53 gene and a herpes
simplex virus thymidine kinase gene downstream of the 3
region of homology. Following positive (G418) and negative
(FIAU) drug selection of the ES cells, 600 surviving clones
were screened by Southern analysis, and 3 clones were identi-
fied that had undergone targeting of the p53 allele.
Detailed analysis of these three clones with 5 and 3 probes
external to the targeting vector confirmed proper targeting of
the locus (Fig. 1B). Two of these clones (A18-6 and A18-11)
were used to perform blastocyst injection experiments, and
both clones gave rise to multiple high-degree chimeras. Male
chimeras were crossed with C57BL/6 mice to obtain agouti F1
offspring. Analysis of genomic DNA isolated from tail biopsies
of these mice confirmed that a subset of the mice had inherited
the targeted allele and had excised the neomycin drug selection
marker due to expression of the protamine-Cre transgene (en-
dogenous in PC3 ES cells, Fig. 1B). The presence of the mu-
tation encoding the Ala18 substitution was confirmed in a
FIG. 1. Mutation of serine 18 in the p53 gene. (A) The targeting
vector encodes a serine to alanine missense mutation in exon 2. An
XhoI restriction site was also deleted in this exon as a diagnostic
marker. A floxed neor gene was introduced in intron 1 to permit
positive selection of ES cells. Homologous recombination of the tar-
geting vector in ES cells is illustrated. The neo gene will be excised in
the sperm of chimeric mice due to expression of a protomine-Cre
transgene present in the PC3 ES cells. The p53Ala18 allele is shown at
the bottom. Probes used for Southern blot analysis are shown (hatched
boxes). (B) Southern blot analysis of targeted ES cell DNA with a 5
external probe (left panel). EcoRI digestionof ES cell DNA indicates
the presence of the mutant allele (unexcised neor gene, 6 kb) and the
wild-type allele (14 kb). Southern blot analysis of F1 progeny with EX7
probe (right panel). An AvrII digest distinguishes the wild-type allele
(4 kb), unexcised mutant allele (8.2 kb), and excised mutant allele (6.7
kb). (C) The presence of the mutation was determined by PCR am-
plification of exon 2 and loss of the XhoI restriction site. (D) Diagram
of the mutation generated in exon 2 of p53. Serine18 was mutated to
an alanine. An adjacent XhoI restriction site was deleted for diagnostic
purposes.
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subset of F1 mice by DNA sequencing and PCR analysis (Fig.
1C). Inheritance of the p53Ala18 allele was subsequently fol-
lowed in the colony by use of a PCR strategy that used the
newly deleted XhoI site in exon 2 adjacent to the Ala18 mu-
tation. Mice heterozygous for the p53Ala18 allele were inter-
crossed, and mice homozygous for the mutant allele were re-
covered at the expected frequency of 25%. Mice heterozygous
or homozygous for the p53Ala18 allele developed normally.
Large cohorts of p53Ala18/ and p53Ala18/Ala18 mice were
generated for further analysis.
In vivo analysis of apoptosis in p53Ala18/Ala18 cells. Mouse
thymocytes are induced to undergo p53-dependent apoptosis
following ionizing radiation treatment (12, 40). To determine
the contribution of p53 ser18 phosphorylation to p53 apopto-
sis, we compared apoptosis in thymocytes of p53Ala18/Ala18
mice and in wild-type mice and p53-null mice following expo-
sure to DNA damage. Thymocytes were recovered from non-
treated mice and from treated mice at 8 h after whole-body
exposure of the mice to 8 Gy of ionizing radiation. The thy-
mocytes were analyzed for apoptosis by analyzing sub-G1 DNA
content (Fig. 2A). Following DNA damage, a similar increase
in the percentage of apoptotic cells was observed in wild-type
thymocytes and in thymocytes bearing one copy of the
p53Ala18 allele, suggesting that the presence of the p53Ala18
allele was not exerting a dominant negative effect on wild-type
p53 (Fig. 2A). However, mice homozygous for p53Ala18 dis-
played significant reductions in the percentage of thymocytes
undergoing apoptosis following DNA damage (Fig. 2B), indi-
cating that phosphorylation of p53 serine 18 does alter p53-
mediated apoptosis in vivo.
CD4/CD8 thymocytes undergo p53-dependent apoptosis fol-
lowing ionizing radiation damage (40). Mice were irradiated in
vivo with 8 Gy, and a time course of CD4/CD8 staining was
performed post-ionizing radiation with multiple p53Ala18/
Ala18, wild-type, and p53-deficient mice. A significant deple-
tion of CD4/CD8 thymocytes was observed in p53Ala18/Ala18
mice (Fig. 2C). p53Ala18/Ala18 mice most closely resembled
the phenotype of p53-heterozygous mice. The fraction of sur-
viving thymocytes was also measured at multiple time points
postirradiation by staining cells for annexin V and 7AAD (Fig.
2D). Annexin V (an early marker for apoptosis)-negative and
7AAD (a DNA intercalator)-negative populations were deter-
mined and compared to untreated thymocytes. The reduced
viability of thymocytes in p53Ala18/ala18 mice confirmed that
these cells were compromised in p53-dependent apoptosis.
To investigate if p53 apoptosis is altered in a different cell
context, splenocytes were also harvested and analyzed for the
percentage of cells undergoing p53-mediated apoptosis follow-
ing whole-body ionizing radiation treatment (Fig. 2F). Similar
to the results obtained with thymocytes, the p53Ala18/Ala18
splenocytes showed increased viability relative to wild-type
splenocytes, indicating that p53-mediated apoptosis was also
compromised in these cells.
Analysis of the role of p53 serine 18 phosphorylation in p53
stability. Phosphorylation of serine 18 has been proposed to
inhibit Mdm2-p53 complex formation (55), leading to the sta-
bilization of p53 levels by preventing Mdm2 from targeting p53
for ubiquitination and proteosomal degradation. Therefore,
reduction in p53Ala18/Ala18 thymocyte apoptosis might re-
flect differences in the stabilization of p53 levels by phosphor-
ylation. To explore this possibility, we examined the basal level
of p53 and DNA damage-induced levels of p53 in wild-type
and p53Ala18/Ala18 thymocytes. As expected, p53 was
strongly induced in these cells 8 h after whole-body irradiation
of mice (Fig. 3). However, no difference was detected between
the basal p53 levels or the p53 levels induced by ionizing
radiation in wild-type and p53Ala18/Ala18 thymocytes. In ad-
dition, while expression of p53-responsive genes such as p21 is
upregulated in thymocytes following ionizing radiation, no de-
fect was observed in the p21 induction in p53Ala18/Ala18
thymocytes. In contrast, induction of the proapoptotic gene
PUMA was decreased in p53Ala18/Ala18 cells relative to p53
wild-type cells. PUMA has recently been shown to be the
principal mediator of p53-dependent death in thymocytes (25).
Analysis of the growth characteristics of p53Ala18/Ala18
embryonic fibroblasts. The rate of embryonic fibroblast pro-
liferation (22, 29) and cell cycle arrest in response to ionizing
radiation damage (31) is p53 dependent. To explore a role for
p53 serine 18 phosphorylation in p53-mediated control of cell
growth, we generated murine embryonic fibroblasts (MEFs)
from wild-type, p53Ala18/Ala18, and p53-deficient embryos
(day 13.5). Studies on bromodeoxyuridine uptake by these cells
revealed no difference between wild-type and p53Ala18/Ala18
MEFs (data not shown). The rate of cell proliferation was
indistinguishable between these two cell populations (Fig. 4A).
To determine if p53Ser18 phosphorylation alters p53-medi-
ated cell cycling, we analyzed the p53-dependent G1 arrest
post-ionizing radiation. We treated cells with 8 Gy of ionizing
radiation and analyzed cell cycle profiles at 18 h postirradiation
by fluorescence-activated cell sorting analysis. Three lines of
p53Ala18/Ala18 MEFs generated from different mice were
analyzed. Similar to wild-type MEFs, p53Ala18/Ala18 MEFs
displayed a large loss of S phase following ionizing radiation
treatment, with values indistinguishable from wild-type cells
(Fig. 4B).
Analysis of protein levels revealed no difference between the
basal and ionizing radiation-induced amounts of p53 in wild-
type and p53Ala18/Ala18 MEFs, and while Mdm2 and p21
levels were both increased by treatment of the cells with ion-
izing radiation, the levels of Mdm2 and p21 were similar in
wild-type and p53Ala18/Ala18 MEFs (Fig. 4C). These data
indicate that phosphorylation does not alter the level of p53
protein in MEFs and is not required for induction of p21.
Immortalization of p53Ala18/Ala18 MEFs. Spontaneous im-
mortalization of embryonic fibroblasts is also dependent upon
p53 function, and p53-null MEFs display rapid immortaliza-
tion in a 3T3 assay, whereas wild-type MEFs do not immor-
talize or show delayed immortalization in these assays (22). To
assess the contribution of p53 serine 18 phosphorylation to
immortalization, a modified 3T3 assay was performed with
multiple plates of two individual lines of p53Ala18/Ala18
MEFs and one line of p53Ala18/ MEFs (Fig. 5A). Whereas
p53-null MEFs immortalized after passage 4 in the assay and
continued to grow rapidly, p53Ala18/Ala18 MEFs stopped di-
viding by passage 8 and failed to spontaneously immortalize.
p53Ala18 allele fails to rescue Mdm2-null mice. As p53
levels are unchanged by the presence of the p53Ala18 muta-
tion, it is unlikely that phosphorylation alters Mdm2-p53 com-
plex formation. We previously demonstrated the importance of
Mdm2-mediated downregulation of p53 activity in early devel-
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opment: Mdm2-null mice die between day 5 and 6 of devel-
opment but are rescued by deletion of p53 (28, 45). It is
presently unclear which p53 functions are inhibited by Mdm2
during embryogenesis. As loss of p21 fails to rescue Mdm2-
nullizygous mice, it has been proposed that unregulated p53
apoptosis is responsible for the early demise of the Mdm2-null
mice (44). However, the paucity of tissue in the Mdm2 null
embryos makes it difficult to determine the precise p53 func-
tions regulated by Mdm2 in this early stage of development. In
order to explore whether reduced apoptotic functions of
p53Ala18 would rescue Mdm2-null mice, we crossed
Mdm2/ mice with p53Ala18 mice as well as intercrossed
Mdm2/ p53Ala18/Ala18 mice. Genotyping of the Mdm2
and p53Ala18 status of the resulting pups determined that,
unlike p53/, p53Ala18/Ala18 does not rescue the embryonic
lethality of Mdm2-null mice (Table 1).
Absence of spontaneous tumorigenesis in p53Ala18 mice. To
determine if phosphorylation of p53 serine 18 is required for
tumor suppression, cohorts of p53Ala18/Ala18 mice were col-
lected and assayed for spontaneous tumor formation. At
present, we have 30 p53Ala18/Ala18 mice that are between 40
and 60 weeks of age. Although 100% of p53-null mice and 25%
of p53-heterozygous mice (21) succumbed to cancer by 40
FIG. 3. Mutation of p53Ser18 does not affect basal or ionizing
radiation-induced levels of p53 protein. Western analysis of extracts
from irradiated (20 Gy) and nonirradiated thymocytes. Extracts were
prepared at 0 h (nonirradiated) or 8 h after ionizing radiation treat-
ment. -Tubulin was used as a control for the Western blot. WT, wild
type.
FIG. 2. p53-mediated apoptosis is defective in p53Ala18 mice.
(A) Analysis of sub-G1 content of thymocytes removed from irradiated
and unirradiated animals (8 Gy, 8 h posttreatment). The y axis depicts
cell number, and the x axis represents DNA content. The percentage of
sub-G1 cells is given for each sample. WT, wild type. (B) Histograph of
sub-G1 DNA from irradiated and nonirradiated mice. Two indepen-
dent animals were analyzed in triplicate for each genotype. (C) Time
course of CD4 CD8 profile of mice irradiated (8 Gy) in vivo and
nonirradiated mice. The graph depicts double-positive cells. (D) Via-
bility of thymocytes over time in response to ionizing radiation. Thy-
mocytes were removed from mice, irradiated (8 Gy), and harvested at
various times (0, 8, 16, and 24 h). Cells were stained with annexin
V-fluorescein isothiocyanate, anti-CD4, and 7AAD. Values given are
the averages of the viable population (annexin V-fluorescein isothio-
cyanate and 7AAD negative) and are normalized to the number of
viable cells in the untreated animal for each genotype. (E) Apoptosis
in splenocytes is reduced in p53Ala18 mice. Splenocytes were prepared
and plated (2 105 cells). Cells were irradiated with 8 Gy. Cell viability
was determined 7 days post-ionizing radiation. The x axis represents
time (days), and the y axis represents viability relative to unirradiated
control cells.
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weeks of age, we have had no incidence of tumorigenesis in any
of our p53Ala18/Ala18 mice, indicating that the reduced apo-
ptotic activity of the mutant p53Ala18 does not alter p53 tumor
suppression.
DISCUSSION
It is becoming increasingly apparent from numerous in vitro
experiments that p53 is highly posttranslationally modified by
phosphorylation. Several studies have demonstrated that p53
serine 18 is phosphorylated in vitro by the ATM and ATR
kinases (3, 8, 33, 46, 51, 58). Analysis of p53 protein levels and
p53 phosphorylation in ATM-deficient cells has suggested that
phosphorylation of this residue by ATM helps regulate the
stability of p53 following DNA damage (3, 8, 32, 56). In addi-
tion, it has been suggested that modification of this serine
regulates p53 stability by altering Mdm2-p53 interactions (55).
However, the role of serine phosphorylation in p53 stability has
been placed in question by the results of other transient trans-
fection studies with a mutant p53 that lacks all amino-terminal
phosphorylation sites (2).
In order to better understand the role of p53 serine 18
phosphorylation in regulating p53 stability and functions, we
generated mice bearing a missense mutation (p53Ser18 to
Ala18) and analyzed p53 functions in p53Ala18 mice and in
primary cells derived from these mice. Our in vivo analysis of
p53Ala18 thymocyte and splenocyte apoptosis revealed a clear
reduction in p53 apoptotic activity when p53Ser18 was incapa-
ble of being phosphorylated. This result is in agreement with a
previous report of diminished p53 apoptosis in p53Ala18 ES
cells (10) and suggests that phosphorylation of this residue by
ATM and ATR contributes to the p53 apoptotic response.
While this article was being prepared for submission, an
independent group reported a defect in cell cycle arrest and an
apoptotic defect in a p53Ala18 mouse model (9). In contrast,
the ability of p53 to regulate cell proliferation and to invoke
cell cycle arrest following DNA damage was unaltered in the
p53Ala18 MEFs, indicating that modification of this residue
does not affect the ability of p53 to regulate cell growth. Thus,
apoptosis and cell growth arrest are p53 functions that are
distinctly regulated by p53Ser18 phosphorylation.
Interestingly, the amount of p53 protein in wild-type and
p53Ala18 thymocytes and MEFs was similar under basal and
DNA damaging conditions, indicating that Mdm2 is properly
regulating the stability of p53Ala18 in these cells. In addition,
p53Ala18 homozygosity failed to rescue Mdm2 deficiency dur-
ing embryogenesis. Since the absence of Mdm2 is lethal to both
wild-type p53 and p53Ala18/Ala18 embryos, Mdm2 must still
govern p53Ala18 activity in development. Thus, phosphoryla-
tion of serine 18 does not alter Mdm2 regulation of p53 sta-
bility in these cells.
The cyclin-dependent kinase inhibitor p21 is a major regu-
lator of the G1 to S transition of the cell cycle and has been
shown previously to be upregulated by p53 (6, 13, 16, 20). Cell
growth and ionizing radiation-induced G1 arrest was not com-
promised in p53Ala18 cells in vivo or in MEFs. In agreement
FIG. 4. (A) Proliferation of wild-type, p53Ala18, and p53-null
MEFs. (B) Histograph of percent of MEFs in S phase (treated or
untreated). MEFs were treated with ionizing radiation and pulsed with
bromodeoxyuridine 15 to 18 h postirradiation. Three independent
lines of p53Ala18 MEFs were analyzed. (C) Western analysis of ex-
tracts from irradiated (8 Gy) and nonirradiated wild-type MEFs and
p53Ala18 MEFs harvested at 5 and 18 h post-ionizing radiation treat-
ment. -Tubulin was used as a control for the Western blot.
FIG. 5. Immortalization is not induced in p53Ala18 MEFs. 3T3
analysis of two independent p53Ala18/Ala18 MEFs compared to
p53Ala18/, MEFs, and p53-null MEFs.
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with these findings, the levels of p21 were not reduced below
wild-type levels in the p53Ala18 MEFs or thymocytes. Apo-
ptosis was compromised in p53Ala18 cells, and the proapo-
ptotic PUMA protein was found to be downregulated in
p53Ala18 thymocytes. As p53 protein levels do not differ in
p53Ser18 and p53Ala18 cells, these results indicate that phos-
phorylation of p53Ala18 likely regulates the ability of p53 to
transactivate apoptotic genes.
The growth rate of mouse embryonic fibroblasts is signifi-
cantly increased following deletion of a single p53 allele (22),
and p53 haploinsufficiency is sufficient to predispose mice to
spontaneous tumorigenesis without loss of heterozygosity for
functional p53 in tumors (61). These results indicate that even
a partial reduction in p53 activity can alter cell growth in some
context and interfere with p53-mediated tumor suppression.
However, the reduced levels of p53 apoptotic function in the
p53Ala18 mice still induced the embryonic demise of Mdm2-
null mice and prevented tumorigenesis in p53Ala18/Ala18
mice. These findings indicate either that cell cycle arrest is an
important component of p53-mediated tumor suppression and
regulation of development or that p53-induced apoptosis is not
rate limiting in these situations.
The role of ATM in cell growth and tumor suppression has
been well established (4, 17, 57, 64, 68). The ATM and the
related ATR kinase have been demonstrated to regulate p53
activity. In vitro studies have provided evidence suggesting that
ATM/ATR-induced phosphorylation of p53 amino-terminal
serines regulates p53 function. In addition to phosphorylating
p53Ser18, ATM has been proposed to influence Chk2-medi-
ated phosphorylation of p53Ser20 (p53Ser23 in the mouse)
following DNA damage (24, 54, 59). However, p53 stability
and p53 transactivation of gene expression were found recently
to be unaltered in thymocytes and MEFs derived from chi-
meric mice generated by using p53Ala23 ES cells (67). These
findings suggest that p53Ser18 must be the key regulatory
target of ATM/ATR phosphorylation. Although p53 apoptosis
was partially compromised in our p53Ala18 model, it is clear
from our data that ATM and ATR must rely upon targets
other than serine 18 to fully regulate p53 activity in response to
DNA damage and to suppress tumor formation.
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